Results 311 to 320 of about 94,528 (347)
Some of the next articles are maybe not open access.
Prospects for adoptive T cell therapy
Current Opinion in Immunology, 1997Since the establishment of methods to isolate genes encoding cytotoxic T lymphocyte defined tumor antigens, several antigens have been identified and characterized for suitability as target antigens for immunotherapy. The development of innovative strategies to generate T cells targeting these antigens and lessons learned from clinical trials of ...
C, Yee, S R, Riddell, P D, Greenberg
openaire +2 more sources
Adoptive cell therapy in multiple Myeloma
Expert Opinion on Biological Therapy, 2017Recent breakthrough advances in Multiple Myeloma (MM) immunotherapy have been achieved with the approval of the first two monoclonal antibodies, elotuzumab and daratumumab. Adoptive cell therapy (ACT) represents yet another, maybe the most powerful modality of immunotherapy, in which allogeneic or autologous effector cells are expanded and activated ex
Sonia, Vallet +2 more
openaire +2 more sources
Neoantigen-Specific T Cells in Adoptive Cell Therapy
The Cancer Journal, 2022Abstract The holy grail of cancer therapeutics is the destruction of cancer cells while avoiding harm to normal cells. Cancer is unique from normal tissues because of the presence of somatic mutations that accumulate during tumorigenesis.
openaire +2 more sources
Seminars in hematology, 1999
Adoptive immunotherapy, or the transfer of immunocompetent cells, has been shown to be a promising new strategy for treatment of a variety of malignancies, including leukemia and non-Hodgkin's lymphoma. The possibility that it may likewise benefit patients with multiple myeloma is now being explored by researchers in Europe and the United States.
Lokhorst, H.M., Liebowitz, D.
openaire +2 more sources
Adoptive immunotherapy, or the transfer of immunocompetent cells, has been shown to be a promising new strategy for treatment of a variety of malignancies, including leukemia and non-Hodgkin's lymphoma. The possibility that it may likewise benefit patients with multiple myeloma is now being explored by researchers in Europe and the United States.
Lokhorst, H.M., Liebowitz, D.
openaire +2 more sources
Adoptive Cell Therapy for Metastatic Melanoma
The Cancer Journal, 2017Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TILs) is a powerful form of immunotherapy by inducing durable complete responses that significantly extend the survival of melanoma patients. Mutation-derived neoantigens were recently identified as key factors for tumor recognition and rejection by TILs.
Efrat, Merhavi-Shoham +4 more
openaire +2 more sources
Adoptive T-Cell Therapy of Cancer
Hematology/Oncology Clinics of North America, 2006Adoptive therapy involves the transfer of ex vivo expanded immune effector cells to patients as a means of augmenting the antitumor immune response. In general, this transfer is accomplished by harvesting cells from the peripheral blood, tumor sites, or draining lymph nodes and expanding effector cells in a specific or nonspecific fashion for adoptive ...
openaire +2 more sources
Adoptive Cell Therapy: Past, Present and Future
Immunotherapy, 2017The immune system is a potent inhibitor of tumor growth with curative potential, constituting in many eyes the future of antineoplastic therapy. Adoptive cell therapy (ACT) is a form of immunotherapy in which autologous cancer-cognate lymphocytes are expanded and modified ex vivo and re-infused to combat the tumor. This review follows the evolvement of
Jonathan E, Cohen +5 more
openaire +2 more sources
Adoptive Cell Therapy for Melanoma
2018Melanoma is a highly immunogenic cancer, and along with the combination of poor clinical outcomes and treatments with limited efficacy, these attributes have made metastatic melanoma an ideal platform to study immune-based therapies. Adoptive cell therapy (ACT) is as a highly effective personalized cancer treatment, utilizing the natural effector ...
Jane Mills +2 more
openaire +1 more source
Adoptive T cell therapy for ovarian cancer
Gynecologic OncologyAlthough ovarian cancer patients typically respond to standard of care therapies, including chemotherapy and DNA repair inhibitors, the majority of tumors recur highlighting the need for alternative therapies. Ovarian cancer is an immunogenic cancer in which the accumulation of tumor infiltrating lymphocytes (TILs), particularly T cells, is associated ...
Sarah B, Gitto +2 more
openaire +2 more sources
Adoptive cell therapy: Honing that killer instinct
Nature, 2013Genetically altered immune cells are helping to push life-threatening cancers into remission and generating a buzz.
openaire +2 more sources